There has been extensive evidence supporting the survival benefit of adjuvant therapy in pancreatic ductal adenocarcinoma (PDAC) regardless of nodal status.
1 Even for premalignant pancreatic lesions such as intraductal papillary mucinous neoplasms (IPMN), various studies endorse an improvement in survival with adjuvant therapy, particularly in the context of node-positive disease.
2 However, for invasive mucinous cystic neoplasms (MCN) of the pancreas, the utility of adjuvant systemic therapy has not been comprehensively studied, and the international consensus guidelines have not explicitly commented on the post-resection management for these patients. Thus, there is a need to understand whether adjuvant therapy is warranted in patients with invasive MCNs, and which subsets of patients would benefit the most. …
